Phase 1/2/3

Kincell Bio and RegCell partner to bring a groundbreaking, non-gene-edited Treg cell therapy for autoimmune diseases from the lab to clinical trials.

From its unique seat at the World Government Summit, CanSinoBIO unveils its next-gen vaccine pipeline and global strategy to fight humanity's oldest diseases.

With five conferences in its sights, Voyager Therapeutics is making a major push to win over investors ahead of a pivotal year for its neurological pipeline.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

With a promising spinal cord injury drug nearing late-stage trials, NervGen appoints interim leader Dr. Adam Rogers as permanent CEO to guide the breakthrough.

A world-first trial for personalized mRNA vaccines offers new hope for children with aggressive brain tumors, a mission born from a father's own fight.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

Caribou Biosciences unveils new data showing its 'off-the-shelf' CAR-T cells achieve deep, lasting responses in lymphoma and myeloma clinical trials.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

Estrella Immunopharma unveils promising Phase 1 data for its next-gen T-cell therapy, but can it overcome a crowded market and its own financial hurdles?

New multi-year data for Fabry and Pompe disease therapies from Amicus Therapeutics showcases sustained benefits, offering new hope for long-term patient outcomes.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

A next-gen immunotherapy enters trials, hoping its safer design can unlock the immune system and form a potent combo against advanced solid tumors.

Early clinical results for MP0712, a novel Radio-DARPin, suggest a breakthrough for targeting aggressive cancers like SCLC while sparing healthy tissue.

CERo Therapeutics reports early safety success and dose escalation in its Phase 1 AML trial for CER-1236, a novel cell therapy for high-risk patients.